{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:26:47Z","timestamp":1790533607458,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.pbb.2022.173492","type":"journal-article","created":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T17:35:51Z","timestamp":1668360951000},"page":"173492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Implications of the endocannabinoid system and the therapeutic action of cannabinoids in autism spectrum disorder: A literature review"],"prefix":"10.1016","volume":"221","author":[{"given":"Rick Wilhiam","family":"de Camargo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin\u00e9rio Ribeiro","family":"de Novais J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa Mendes","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Meneguzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Cabreira","family":"Daros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Goulart","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Mariano","family":"de Bitencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2022.173492_bb0005","series-title":"DSM-5 Update: Supplement to Diagnostic and Statistical Manual of Mental Disorders","year":"2017"},{"issue":"2","key":"10.1016\/j.pbb.2022.173492_bb0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jamapediatrics.2018.4208","article-title":"Prevalence and treatment patterns of autism Spectrum disorder in the United States","volume":"173","author":"Xu","year":"2019","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.pbb.2022.173492_bb0015","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1146\/annurev-physiol-022516-034406","article-title":"Microglia in physiology and disease","volume":"79","author":"Wolf","year":"2017","journal-title":"Annu. Rev. Physiol."},{"issue":"6","key":"10.1016\/j.pbb.2022.173492_bb0020","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00213-013-3140-7","article-title":"Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care","volume":"231","author":"Murray","year":"2014","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.pbb.2022.173492_bb0025","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1089\/cap.2012.0075","article-title":"Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change","volume":"23","author":"Mankoski","year":"2013","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"10.1016\/j.pbb.2022.173492_bb0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40272-019-00333-x","article-title":"Safety and tolerability of antipsychotic medication in individuals with autism Spectrum disorder: a systematic review and meta-analysis","volume":"21","author":"Alfageh","year":"2019","journal-title":"Pediatr. Drugs"},{"key":"10.1016\/j.pbb.2022.173492_bb0035","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jpsychires.2021.02.048","article-title":"Potential of cannabinoids as treatments for autism Spectrum disorders","volume":"137","author":"Nezgovorova","year":"2021","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.pbb.2022.173492_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13229-021-00420-2","article-title":"Cannabinoid treatment for autism: a proof-of-concept randomized trial","volume":"12","author":"Aran","year":"2021","journal-title":"Mol. Autism"},{"issue":"3","key":"10.1016\/j.pbb.2022.173492_bb0045","first-page":"180","article-title":"Medicinal cannabis: history, pharmacology, and implications for the acute care setting","volume":"42","author":"Bridgeman","year":"2017","journal-title":"P T."},{"issue":"2","key":"10.1016\/j.pbb.2022.173492_bb0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2009.02.010","article-title":"The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation","volume":"60","author":"Di Marzo","year":"2009","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pbb.2022.173492_bb0055","first-page":"7","article-title":"Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?","volume":"32","author":"Saito","year":"2010","journal-title":"Rev. Bras. Psiquiatr."},{"issue":"12","key":"10.1016\/j.pbb.2022.173492_bb0060","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/0040-4020(63)85022-X","article-title":"The structure of cannabidiol","volume":"19","author":"Mechoulam","year":"1963","journal-title":"Tetrahedron"},{"issue":"3","key":"10.1016\/j.pbb.2022.173492_bb0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00432554","article-title":"Action of cannabidiol on the anxiety and other effects produced by \u03b49-THC in normal subjects","volume":"76","author":"Zuardi","year":"1982","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2022.173492_bb0070","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/ejn.12431","article-title":"The molecular interplay between endocannabinoid and neurotrophin signals in the nervous system and beyond","volume":"39","author":"Keimpema","year":"2014","journal-title":"Eur. J. Neurosci."},{"issue":"25","key":"10.1016\/j.pbb.2022.173492_bb0075","doi-asserted-by":"crossref","first-page":"10264","DOI":"10.1523\/JNEUROSCI.4171-12.2013","article-title":"Cannabinoid CB1 receptor in dorsal telencephalic glutamatergic neurons: distinctive sufficiency for hippocampus-dependent and amygdala-dependent synaptic and behavioral functions","volume":"33","author":"Ruehle","year":"2013","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.pbb.2022.173492_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13229-018-0203-y","article-title":"Plasma anandamide concentrations are lower in children with autism spectrum disorder","volume":"9","author":"Karhson","year":"2018","journal-title":"Mol Autism."},{"key":"10.1016\/j.pbb.2022.173492_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.01521","article-title":"Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities","volume":"9","author":"Barchel","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2022.173492_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-37570-y","article-title":"Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy","volume":"9","author":"Bar-Lev Schleider","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pbb.2022.173492_bb0095","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s10803-018-3808-2","article-title":"Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems-a retrospective feasibility study","volume":"49","author":"Aran","year":"2019","journal-title":"J. Autism Dev. Disord."},{"issue":"3","key":"10.1016\/j.pbb.2022.173492_bb0100","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1017\/S003329171400172X","article-title":"The epidemiology and global burden of autism spectrum disorders","volume":"45","author":"Baxter","year":"2015","journal-title":"Psychol. Med."},{"issue":"6","key":"10.1016\/j.pbb.2022.173492_bb0105","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00213-013-3290-7","article-title":"Biomarkers in autism spectrum disorder: the old and the new","volume":"231","author":"Ruggeri","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173492_bb0110","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.conb.2017.05.018","article-title":"Mitochondrial dysfunction in autism Spectrum disorder: clinical features and perspectives","volume":"45","author":"Hollis","year":"2017","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.pbb.2022.173492_bb0115","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.conb.2014.10.015","article-title":"Autism Spectrum disorders: from genes to neurobiology","volume":"30","author":"Willsey","year":"2015","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.pbb.2022.173492_bb0120","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.neubiorev.2015.05.004","article-title":"Family history of autoimmune diseases is associated with an increased risk of autism in children: a systematic review and meta-analysis","volume":"55","author":"Wu","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"2","key":"10.1016\/j.pbb.2022.173492_bb0125","first-page":"151","article-title":"Maternal autoimmune diseases, asthma and allergies, and childhood autism Spectrum disorders","volume":"159","author":"Cren","year":"2005","journal-title":"Arch Pediatr Adolesc Med."},{"issue":"16","key":"10.1016\/j.pbb.2022.173492_bb0130","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism Spectrum disorders and childhood autism","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.pbb.2022.173492_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.f2059","article-title":"Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study","volume":"346","author":"Rai","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.pbb.2022.173492_bb0140","first-page":"1","article-title":"Folic acid and autism: what do we know?","author":"Castro","year":"2016","journal-title":"Nutr. Neurosci."},{"issue":"4","key":"10.1016\/j.pbb.2022.173492_bb0145","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/ije\/dyq056","article-title":"Prenatal alcohol exposure and autistic spectrum disorders-a population-based prospective study of 80 552 children and their mothers","volume":"39","author":"Eliasen","year":"2010","journal-title":"Int. J. Epidemiol."},{"issue":"3","key":"10.1016\/j.pbb.2022.173492_bb0150","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ppe.12043","article-title":"Smoking during pregnancy and risk of autism spectrum disorder in a finnish national birth cohort","volume":"27","author":"Tran","year":"2013","journal-title":"Paediatr. Perinat. Epidemiol."},{"key":"10.1016\/j.pbb.2022.173492_bb0155","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.envres.2014.04.034","article-title":"Prenatal and neonatal peripheral blood mercury levels and autism spectrum disorders","volume":"133","author":"Yau","year":"2014","journal-title":"Environ. Res."},{"issue":"5","key":"10.1016\/j.pbb.2022.173492_bb0160","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s11011-017-0077-2","article-title":"The putative role of environmental aluminium in the development of chronic neuropathology in adults and children. How strong is the evidence and what could be the mechanisms involved?","volume":"32","author":"Morris","year":"2017","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.pbb.2022.173492_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2021.734837","article-title":"Endocannabinoid system unlocks the puzzle of autism treatment via microglia","volume":"12","author":"Su","year":"2021","journal-title":"Front. Psychiatry."},{"key":"10.1016\/j.pbb.2022.173492_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fncel.2019.00424","article-title":"The endocannabinoid system as a window into microglial biology and its relationship to autism","volume":"13","author":"Araujo","year":"2019","journal-title":"Front. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.pbb.2022.173492_bb0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00021.2003","article-title":"Localized effects of cAMP mediated by distinct routes of protein kinase a","volume":"84","author":"Task\u00e9n","year":"2004","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.pbb.2022.173492_bb0180","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/ijms19030833","article-title":"Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system","volume":"19","author":"Zou","year":"2008","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pbb.2022.173492_bb0185","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2174\/156800705774933023","article-title":"Endocannabinoids in neuroimmunology and stress","volume":"4","author":"Carrier","year":"2005","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.pbb.2022.173492_bb0190","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1517\/14728222.10.5.653","article-title":"Targeting the CB2 receptor for immune modulation","volume":"10","author":"Lunn","year":"2006","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.pbb.2022.173492_bb0195","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1042\/BST20130117","article-title":"Endocannabinoid signals in the developmental programming of delayed-onset neuropsychiatric and metabolic illnesses","volume":"41","author":"Keimpema","year":"2013","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.pbb.2022.173492_bb0200","doi-asserted-by":"crossref","first-page":"13992","DOI":"10.1523\/JNEUROSCI.2126-10.2010","article-title":"Differential subcellular recruitment of monoacylglycerol lipase generates spatial specificity of 2-arachidonoyl glycerol signaling during axonal pathfinding","volume":"30","author":"Keimpema","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2022.173492_bb0205","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/j.1460-9568.2004.03285.x","article-title":"Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity","volume":"19","author":"Khaspekov","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pbb.2022.173492_bb0210","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejphar.2003.08.101","article-title":"The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders","volume":"480","author":"Van der Stelt","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173492_bb0215","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1755-5949.2010.00144.x","article-title":"Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders","volume":"16","author":"Fern\u00e1ndez-Ruiz","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.pbb.2022.173492_bb0220","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2165\/00023210-200317030-00004","article-title":"Therapeutic potential of cannabinoids in CNS disease","volume":"17","author":"Croxford","year":"2003","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.pbb.2022.173492_bb0225","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3390\/ijms18071425","article-title":"Endocannabinod signal dysregulation in autism Spectrum disorders: a correlation link between inflammatory state and neuro-immune alterations","volume":"18","author":"Brigida","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pbb.2022.173492_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnhum.2013.00671","article-title":"Evidence for dysregulation of axonal growth and guidance in the etiology of ASD","volume":"7","author":"McFadden","year":"2013","journal-title":"Front. Hum. Neurosci."},{"issue":"9","key":"10.1016\/j.pbb.2022.173492_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/tp.2016.182","article-title":"Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid","volume":"6","author":"Servadio","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2022.173492_bb0240","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bbi.2016.07.152","article-title":"Deficient adolescent social behavior following early-life inflammation is ameliorated by augmentation of anandamide signaling","volume":"58","author":"Doenni","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.pbb.2022.173492_bb0245","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.phrs.2016.08.033","article-title":"Pharmacological inhibition of fatty acid amide hydrolase attenuates social behavioural deficits in male rats prenatally exposed to valproic acid","volume":"113","author":"Kerr","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pbb.2022.173492_bb0250","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bbr.2013.04.043","article-title":"Alterations in the endocannabinoid system in the rat valproic acid model of autism","volume":"249","author":"Kerr","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2022.173492_bb0255","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.expneurol.2017.04.017","article-title":"The valproic acid-induced rodent model of autism","volume":"299","author":"Nicolini","year":"2018","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.pbb.2022.173492_bb0260","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1742-2094-11-78","article-title":"The in vitroGcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages","volume":"11","author":"Siniscalco","year":"2014","journal-title":"J. Neuroinflamm."},{"issue":"11","key":"10.1016\/j.pbb.2022.173492_bb0265","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1007\/s10803-013-1824-9","article-title":"Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders","volume":"43","author":"Siniscalco","year":"2013","journal-title":"J. Autism Dev. Disord."},{"issue":"2","key":"10.1016\/j.pbb.2022.173492_bb0270","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/MOP.0b013e328336eb9a","article-title":"What causes autism? Exploring the environmental contribution","volume":"22","author":"Landrigan","year":"2010","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.pbb.2022.173492_bb0275","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.phrs.2016.08.033","article-title":"Pharmacological inhibition of fatty acid amide hydrolase attenuates social behavioural deficits in male rats prenatally exposed to valproic acid","volume":"113","author":"Kerr","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pbb.2022.173492_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnbeh.2011.00057","article-title":"Effects of endocannabinoid system modulation on cognitive and emotional behavior","volume":"5","author":"Zanettini","year":"2011","journal-title":"Front. Behav. Neurosci."},{"issue":"443","key":"10.1016\/j.pbb.2022.173492_bb0285","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pnpbp.2014.01.019","article-title":"Release of endogenous cannabinoids from ventral tegmental area dopamine neurons and the modulation of synaptic processes","volume":"52","author":"Wang","year":"2014","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.pbb.2022.173492_bb0290","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1172\/JCI131752","article-title":"An endocannabinoid-regulated basolateral amygdala-nucleus accumbens circuit modulates sociability","volume":"130","author":"Folkes","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.pbb.2022.173492_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2019.107736","article-title":"Targeting the inhibition of fatty acid amide hydrolase ameliorate the endocannabinoid-mediated synaptic dysfunction in a valproic acid-induced rat model of autism","volume":"162","author":"Wu","year":"2020","journal-title":"Neuropharmacology"},{"issue":"51","key":"10.1016\/j.pbb.2022.173492_bb0300","doi-asserted-by":"crossref","first-page":"18620","DOI":"10.1073\/pnas.0509591102","article-title":"Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis","volume":"102","author":"Gobbi","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.pbb.2022.173492_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13229-019-0256-6","article-title":"Lower circulating endocannabinoid levels in children with autism spectrum disorder","volume":"10","author":"Aran","year":"2019","journal-title":"Mol Autism."},{"issue":"5","key":"10.1016\/j.pbb.2022.173492_bb0310","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ptr.2625","article-title":"Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders","volume":"23","author":"Scuderi","year":"2009","journal-title":"Phytother. Res."},{"issue":"3","key":"10.1016\/j.pbb.2022.173492_bb0315","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/schbul\/sbz102","article-title":"Transition of substance-induced, brief, and atypical psychoses to schizophrenia: a systematic review and meta-analysis","volume":"46","author":"Murrie","year":"2020","journal-title":"Schizoph Bull."},{"issue":"8","key":"10.1016\/j.pbb.2022.173492_bb0320","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/aur.1977","article-title":"Association between schizophrenia and autism spectrum disorder: a systematic review and meta-analysis: schizophrenia and autism spectrum disorder","volume":"11","author":"Zheng","year":"2018","journal-title":"Autism Res."},{"issue":"7","key":"10.1016\/j.pbb.2022.173492_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biomedicines10071685","article-title":"A placebo-controlled trial of cannabinoid treatment for disruptive behavior in children and adolescents with autism spectrum disorder: effects on sleep parameters as measured by the cshq","volume":"10","author":"Schnapp","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.pbb.2022.173492_bb0330","doi-asserted-by":"crossref","unstructured":"Chen H, Yang T, Chen J, et al. (n.d.) Sleep problems in children with autism spectrum disorder: a multicenter survey. BMC Psychiatry.;21(1):1-13.","DOI":"10.1186\/s12888-021-03405-w"},{"key":"10.1016\/j.pbb.2022.173492_bb0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2019.01145","article-title":"Effects of cbd-enriched cannabis sativa extract on autism spectrum disorder symptoms: an observational study of 18 participants undergoing compassionate use","volume":"10","author":"Fleury-Teixeira","year":"2019","journal-title":"Front. Neurol."},{"issue":"9","key":"10.1016\/j.pbb.2022.173492_bb1000","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s00213-022-06196-4","article-title":"Cannabidiol for the treatment of autism spectrum disorder: hope or hype?","volume":"239","author":"Pedrazzi","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"10.1016\/j.pbb.2022.173492_bb0340","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41386-019-0333-8","article-title":"Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder","volume":"44","author":"Pretzsch","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.pbb.2022.173492_bb0345","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/em.22396","article-title":"Subacute cannabidiol alters genome-wide DNA methylation in adult mouse hippocampus","volume":"61","author":"Wanner","year":"2020","journal-title":"Environ. Mol. Mutagen."},{"issue":"9","key":"10.1016\/j.pbb.2022.173492_bb0350","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1007\/s10803-021-05254-8","article-title":"Brief report: suspected cannabis-induced mania and psychosis in young adult males with autism spectrum disorder","volume":"52","author":"Al-Soleiti","year":"2022","journal-title":"J. Autism Dev. Disord."},{"issue":"8","key":"10.1016\/j.pbb.2022.173492_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/healthcare10081553","article-title":"Cannabis use in autism: reasons for concern about risk for psychosis","volume":"10","author":"Bortoletto","year":"2022","journal-title":"Healthcare"},{"issue":"6","key":"10.1016\/j.pbb.2022.173492_bb0360","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S1734-1140(09)70161-6","article-title":"Cannabinoid CB1 receptors in rat medial prefrontal cortex are colocalized with calbindin- but not parvalbumin- and calretinin-positive GABA-ergic neurons","volume":"61","author":"W\u0229dzony","year":"2009","journal-title":"Pharmacol Reports."},{"issue":"1","key":"10.1016\/j.pbb.2022.173492_bb0365","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.mcn.2008.09.001","article-title":"TRPV1 channels facilitate glutamate transmission in the striatum","volume":"40","author":"Musella","year":"2009","journal-title":"Mol. Cell. Neurosci."},{"issue":"2","key":"10.1016\/j.pbb.2022.173492_bb0370","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/sj.bjp.0705931","article-title":"Marijuana and cannabinoid regulation of brain reward circuits","volume":"143","author":"Lupica","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173492_bb0375","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/09540260902782760","article-title":"Basic neuroanatomy and neuropharmacology of cannabinoids","volume":"21","author":"Breivogel","year":"2009","journal-title":"Int. Rev. Psychiatry"},{"issue":"8","key":"10.1016\/j.pbb.2022.173492_bb0380","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.pbb.2022.173492_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.24966\/ACIM-7562\/100066","article-title":"Cannabidiol and contributions of major hemp phytocompounds to the \u201centourage effect\u201d Possible mechanisms","volume":"5","author":"Nahler","year":"2019","journal-title":"Altern. Complement Integr. Med."},{"key":"10.1016\/j.pbb.2022.173492_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2021.777804","article-title":"Minor cannabinoids: biosynthesis, molecular pharmacology and potential therapeutic uses","volume":"12","author":"Walsh","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173492_bb0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2018.00759","article-title":"Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis","volume":"9","author":"Pamplona","year":"2018","journal-title":"Front. Neurol."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009130572200171X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009130572200171X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:45:25Z","timestamp":1758775525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009130572200171X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":80,"alternative-id":["S009130572200171X"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173492","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implications of the endocannabinoid system and the therapeutic action of cannabinoids in autism spectrum disorder: A literature review","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173492"}}